News
In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...
10h
Zacks Investment Research on MSNBiotech Stock Roundup: BMY Down on Study Data, Updates From REGN & MoreThis was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...
Gilead Sciences Q1 earnings report is due April 24. Explore forecasts on revenue growth, EPS expectations, HIV pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results